Nov 23, 2022
In this episode of SurgOnc Today®, Dr. Julie Hallet from the University of Toronto, and Vice-Chair of the SSO HPB disease site working group, is joinded by Dr. James R. Howe from the University of Iowa and Dr. Nadine Mallak from the Oregon Health and Science University. They discuss how somatostatin receptor PET imaging, such as DOTATE-PET, can be used to guide and support the surgical management of pancreatic neuroendocrine tumors.
Moderator:
Julie Hallet MD, Msc;
Associate Professor of Surgery. University of Toronto, Toronto, Canada;
Surgical Oncologist, Susan Leslie Clinic for Neuroendocrine Tumors – Sunnybrook Health Sciences Centre, Toronto, Canada
Vice-Chair, HPB DSWG, SSO
Faculty:
James R. Howe, MD
Professor of Surgery and Director of Surgical Oncology and Endocrine Surgery, Roy J. and Lucille A. Carver University of Iowa College of Medicine, Iowa City, Iowa
Nadine Mallak, MD
Associate Professor, Department of Diagnostic Radiology, Nuclear Medicine and Body Imaging sections
Director, PET/MRI, Clinical, Oregon Health and Science University, Portland, OR
References
NANETS guidelines for the surgical management of pancreatic neuroendocrine tumors
SNMMI appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors
https://s3.amazonaws.com/rdcms-snmmi/files/production/public/Quality/jnm202275_New%20-%20revised.pdf